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Identification of an evolutionary 
conserved structural loop that is 
required for the enzymatic and 
biological function of tryptophan 
2,3-dioxygenase
Helen Michels1, Renée I. Seinstra1, Joost C. M. Uitdehaag2, Mandy Koopman1,  
Martijn van Faassen3, Céline N. Martineau1, Ido P. Kema3, Rogier Buijsman2 & 
Ellen A. A. Nollen1
The enzyme TDO (tryptophan 2,3-dioxygenase; TDO-2 in Caenorhabditis elegans) is a potential 
therapeutic target to cancer but is also thought to regulate proteotoxic events seen in the progression 
of neurodegenerative diseases. To better understand its function and develop specific compounds that 
target TDO we need to understand the structure of this molecule. In C. elegans we compared multiple 
different CRISPR/Cas9-induced tdo-2 deletion mutants and identified a motif of three amino acids 
(PLD) that is required for the enzymatic conversion of tryptophan to N-formylkynurenine. Loss of 
TDO-2’s enzymatic activity in PDL deletion mutants was accompanied by an increase in motility during 
aging and a prolonged lifespan, which is in line with the previously observed phenotypes induced by a 
knockdown of the full enzyme. Comparison of sequence structures suggests that blocking this motif 
might interfere with haem binding, which is essential for the enzyme’s activity. The fact that these 
three residues are situated in an evolutionary conserved structural loop of the enzyme suggests that the 
findings can be translated to humans. The identification of this specific loop region in TDO-2–essential 
for its catalytic function–will aid in the design of novel inhibitors to treat diseases in which the TDO 
enzyme is overexpressed or hyperactive.
Genetic variation, environmental factors and aging can lead to malfunctioning or hyperactive proteins, thereby 
provoking reactions in the cell that might underlie certain diseases. Understanding the structure of such proteins 
is required when aiming to generate disease-specific compounds that interfere with the protein’s function.
One such protein, that has recently attracted the attention as a potential therapeutic target, is tryptophan 
2,3-dioxygenase (TDO in humans, TDO-2 in C. elegans) (e.g. ref. 1 and summarised in refs 2 and 3), a cytosolic 
enzyme that converts tryptophan into formyl kynurenine, thereby catalysing the first rate-limiting step of the 
kynurenine pathway4. In animal models, inhibition or depletion of TDO has been shown to suppress disease phe-
notypes and to prolong lifespan5–9. This is thought to be mediated by inhibition of different tryptophan-related 
pathways that underlie the diseases. For example, since the kynurenine pathway is used to convert 95% of cel-
lular tryptophan, it greatly influences the availability of this amino acid for other tryptophan-related metabolic 
pathways, including, but not limited to, the production of serotonin10. A lack of serotonin has, among others, 
been associated with depression disorders, which are usually treated with selective serotonin re-uptake inhibitors 
(SSRIs) to increase serotonin levels (summarised in ref. 11). Secondly, the kynurenine pathway produces metab-
olites called kynurenines, and an imbalance of certain kynurenines such as kynurenic acid, 3-hydroxykynurenine 
and quinolinic acid is thought to have profound effects on brain function, may cause a range of neuron-associated 
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diseases (e.g. ref. 12 and summarised in ref. 13) and was recently found being associated with diabetes type 
214. Thirdly, overexpression of TDO in certain cancers is thought to increase the tumour’s resistance to the 
T-cell-mediated immune response which might be dependent on tryptophan in the microenvironment15. Since 
the majority of the phenotypes described above are accompanied by overexpression or hyperactivity of TDO, it 
is possible that inhibiting the activity of TDO would increase tryptophan and subsequently serotonin levels and 
control the production of kynurenines.
The development of such compounds requires a thorough understanding of the structure of TDO. Fortunately, 
the conversion of tryptophan by TDO is evolutionarily conserved from yeast to humans16, which means that 
studies in other organisms may provide useful information on both its structure and function. For example, from 
such studies we know that TDO is mainly present as homodimers that can form tetramers to be enzymatically 
active4 and that the enzymatic reaction it catalyses is haem and oxygen-dependent17,18. The haem and tryptophan 
binding sites in human TDO are also known, and the enzyme’s 3D structure was first described by Forouhar and 
colleagues for TDO in the bacterium X. campestris19. While the crystal structure of human TDO has now also 
been reported20, it still remains to be determined which specific amino acids in the TDO polypeptide chains are 
critical for its enzymatic activity.
We created multiple different CRISPR/Cas9-induced deletion mutants of tdo-2 in the nematode C. elegans. A 
comparison of these mutants revealed that three amino acid residues in the loop that is close to the haem moiety 
are essential for the enzymatic activity of TDO-2. The effect of the deletion of those three amino acid residues was 
as severe as that seen for larger truncations of the enzyme. We also found that the loop structure in which these 
three amino acid residues reside, is evolutionary conserved in human.
These findings will aid in the development of very specific inhibitors of TDO to intervene with certain 
disorders.
Results and Discussion
We mutated tdo-2 in C. elegans with the help of the CRISPR/Cas9 method. To increase the chances of generat-
ing truncation mutants we chose a target sequence that was situated the closest to the transcription start. The 
CRISPR/Cas9 system induces double strand breaks at the targeted sequence. Mistakes during the repair process 
can lead to mutations, mainly deletions. We got three different mutants with deletions in exon 3 (Fig. 1a), namely 
tdo-2 (ΔPLD), which lacked 9 bp, tdo-2 (del), which lacked 14 bp, and tdo-2 (del B), which lacked 28 bp. We pre-
dicted that the tdo-2 (del) and tdo-2 (del B) deletions led to a frame shift during translation, resulting in an early 
STOP codon. Indeed, upon immunoblotting we were unable to detect complete TDO-2 proteins in these mutants 
(Fig. 1b). However, the mutant with the 9 bp deletion (tdo-2 (ΔPLD)) produced a protein that was probably 
missing exactly three amino acid residues (Fig. 1a) but that was still detectable with the anti-TDO-2 antibody 
(Fig. 1b).
Figure 1. Deletion of PLD sequence impairs conversion of tryptophan by TDO-2. (a) CRISPR/Cas9-
induced deletions in exon 3 of the tdo-2 gene. (b) Immunodetection of the TDO-2 enzyme in worm lysates 
from day 4 of adulthood (Cropped image, for full length blot see Supplementary Fig. 1a). (c) Schematic 
representation of TDO-mediated conversion of tryptophan to kynurenine in humans and C. elegans.  
(d) Tryptophan and kynurenine levels in worm lysates. Error bars in all panels = SEM. Statistics for all panels, 
one-way ANOVA with post-hoc Bonferroni (comparison with WT): * < 0.05; ** < 0.01; *** < 0.001.
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We then determined whether the deletions resulted in complete knockout mutations. Figure 1c illustrates the 
first part of the kynurenine pathway whereby TDO (TDO-2 in C. elegans) converts tryptophan into formylky-
nurenine, which is further processed to kynurenine. To this end, we measured tryptophan and kynurenine levels 
in C. elegans lysates. Surprisingly, we saw higher tryptophan levels and reduced kynurenine levels not only in 
the samples from animals whose TDO-2 proteins had large truncations, but also in the samples from the ΔPLD 
mutants, suggesting that the three amino acids missing in this mutant are essential for tryptophan conversion by 
TDO-2 (Fig. 1d).
We then checked if the phenotypes of the mutants were the same as those described previously when 
non-mutated animals were treated with tdo-2 RNAi8. Indeed, all three mutants produced fewer hatched 
progeny and had an extended reproductive lifespan (Fig. 2a). They also had increased motility (Fig. 2b and 
Supplementary Fig. S1). Comparing the relationship between time and genotype, the results suggest that 
differences in motility start to appear at day 4 of adulthood and become more consistent at higher ages, sug-
gesting an age-dependent or accumulative effect. All three mutants show similar results (see legends of 
Fig. 2b and Supplementary Fig. S1). Finally, the different mutations all similarly extended lifespan (Fig. 2c). 
To note, the lifespan extension in the three different tdo-2 mutants was similar to each other but less when 
compared to the lifespan extension by RNAi knockdown starting after development8 and also less robust 
(Supplementary data Table S2). This suggests that these germline mutations in tdo-2 may have unknown addi-
tional developmental and health consequences that influence lifespan. Still, taken together our results show that 
the 9 bp Δ PLD deletion is just as effective in mediating TDO-2-specific phenotypes as the removal of almost 
the entire protein, as it is the case for the tdo-2(del) and tdo-2(del B) mutants, indicating that it is an inactivat-
ing mutation. The results also suggest that loss of enzymatic activity of TDO-2 is responsible for the observed 
phenotypes.
Next, to determine why these three amino acid residues might be essential for enzyme activity, we studied the 
sequence and structure of the TDO-2 molecule. When we aligned the sequences of TDO of different organisms 
with that of C. elegans we found that human and C. elegans show a sequence identity of 48.4%. Figure 3a depicts 
a part of the amino acid sequences, highlighting the residues involved in tryptophan binding (yellow) and haem 
binding (red) as described by Forouhar et al.19. Residues forming part of binding sites for both tryptophan and 
haem are shown in orange (The complete sequence alignment is shown in Supplementary Fig. S3). The sequence 
comparison shows a strong homology around the site of the PLD deletion (Fig. 3a, highlighted in blue). Whereas 
Figure 2. PLD motif in TDO-2 is required for regulation of reproduction, motility and lifespan. (a) 
Reproductive behaviour. (b) Motility. Results of interaction by two-way ANOVA considering genotype and 
time: p < 0.001, p < 0.001, p 0.5205. (c) Survival curve of wild type and tdo-2 mutated animals. Error bars in all 
panels = SEM. Statistics for all panels (comparison with WT): ** < 0.01; *** < 0.001.
www.nature.com/scientificreports/
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Figure 3. Deletion of PLD motif in TDO-2 is predicted to destabilise the interaction with haem which is 
essential for enzymatic activity. (a) Part of a multiple sequence alignment of TDO of different organisms and 
C. elegans TDO-2; yellow = tryptophan binding site, red = haem binding site, orange = binding site for haem 
and tryptophan, blue = residues missing in mutant tdo-2 (ΔPLD). (b) X-ray structure of the human TDO 
tetramer (PDB identifier 4PW8, separate monomers in light red, blue, grey and orange), in which a haem group 
has been added to the model according to the 3D structure of TDO from X. campestris (green, PDB identifier 
www.nature.com/scientificreports/
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the frameshift mutants are lacking most of the tryptophan and haem-binding sites (everything downstream of the 
PLD site), the PLD mutation is located in a region surrounded by binding sites for tryptophan and haem.
In order to understand the implications of the PLD deletion, we then studied 3D structures. Because the X-ray 
structure of C. elegans TDO-2 is not known, we generated a model based on the 3D structure of human TDO 
(ref. 20 and Fig. 3b). When enzymatically active, TDO forms a tetramer, as illustrated in the structure depicted in 
Fig. 3b (monomers in grey, orange, blue and light red). The structure shows that the sequence has a flexible loop 
(MSPLDF-motif, depicted in green) that connects two alpha-helices that together interact with the haem moiety 
(green), which is important for the catalytic activity of TDO (ref. 19 and Fig. 3b). This loop is enlarged in Fig. 3c 
to show the interactions between different TDO monomers that stabilize the final enzyme structure as well as the 
binding to tryptophan (orange) and haem (green, Fig. 3c).
The tdo-2 (del) and tdo-2 (delB) mutant proteins are missing the entire ‘lid’ of the catalytic site, which is found 
on the C-terminal side of the MSPLDF loop (indicated red in Fig. 3b), explaining the lack of catalytic activity and 
the increased levels of tryptophan in these mutant animals.
We also generated a model for the PLD deletion mutant. The PLD deletion leaves the TDO-2 structure largely 
intact (Fig. 3d, right-hand panel). However, it shortens the MSPLDF loop (compare enlarged images of WT 
and tdo-2 (ΔPLD) models in Fig. 3d, left and right-hand panels) and removes Asp135 (signified by the D in 
PLD). This Asp135 residue interacts with lysine (Lys106) and arginine (Arg113) on a neighbouring chain and, the 
absence of such interaction most likely destabilises the protein’s quaternary structure (Fig. 3b). The PLD deletion 
also removes Pro133 (signified by the P in PLD), and proline is an amino acid residue known to provide rigidity 
to turns in protein structures. Based on the important structural functions of these two amino acids, we suggest 
that the PLD deletion introduces too much flexibility in the MSPLDF loop connecting helix α C and α D of the 
C. elegans TDO-2 structure (nomenclature of the alpha helices according to ref. 19) (Fig. 3c). Furthermore, as 
demonstrated in the X. campestris TDO X-ray structure19, the binding of tryptophan to an Arg in the α D helix by 
salt bridges is key to substrate-enzyme binding (Arg 117 in X. campestris as indicated in Fig. 3c, which is equiva-
lent to Arg140 in C. elegans and Arg 144 in H. sapiens). Subtle disturbances in the positioning of this helix could 
be the main cause of the protein’s loss of enzymatic activity. In support of this, Dolušić et al.21 have shown that 
TDO inhibitors 680C91 and LM10 both strongly interact with the α D helix, thereby emphasizing the importance 
of our finding for the design of novel specific TDO inhibitors21.
Upon studying the conservation of the PLD sequence in several species, we noted that in humans and many 
other species the proline is replaced by an alanine (resulting in ALD, Fig. 3a). Therefore, a model of human TDO 
with an ALD deletion (hTDO (Δ ALD)) (Fig. 3e) was generated as well. The ALD deletions shortens the loop 
connecting the α C and α D helices similar to the PLD deletion in the C. elegans enzyme. Loss of the aspartate 
(D) leads to a loss of connections to Arg 375, Lys 110 and Arg 117 in the neighbouring monomer, resulting in 
expected loss of the stability of the quaternary structure. Though the alanine in ALD does not provide intrinsic 
loop stability as the proline in PLD does, it is part of the N-terminal moiety of an α -helix. Disruption of this 
N-terminus through deletion of the ALD sequence will lead to destabilization of the entire helix and will impact 
the interaction of Arg 117 (X. campestris numbering, Arg140 in C. elegans and Arg 144 in H. sapiens) with the 
substrate (Fig. 3c–e). Deletion of the ALD motif will, therefore, likely abrogate activity in human TDO and other 
ALD containing orthologs.
Of the three CRISPR/Cas9-induced mutations in the tdo-2 gene studied here, two resulted in truncated pro-
teins (early stop codon mutations). While the third mutant was lacking only three amino acids (PLD motif), it 
also had deficits when considering the conversion of tryptophan to kynurenine and a concomitant increase in 
motility and a prolonged lifespan. Thus, we have identified a stretch of amino acids in the TDO polypeptide chain 
that is situated in an evolutionary conserved loop that appears to be critical for this protein’s enzymatic activity.
The early stop codon mutations seem to distort the top half of the active site of TDO-2, preventing binding of 
tryptophan and haem. Depletion of the PLD motif introduces flexibility in the loop connecting the α D and α C 
helixes, thereby likely disturbing the α D helix and destabilizing the quaternary structure of the TDO-2 complex.
Interestingly, the loop containing the ALD motif of TDO has never before been identified as being crucial for 
enzyme activity. This finding will help to develop a new family of TDO-specific inhibitors that can target and destabi-
lise this particular loop region, with the overall aim of treating TDO hyperactivity and tryptophan-associated diseases.
Methods
Media and strains. Animals were maintained at 20 °C on Nematode Growth Medium (NGM) and fed with 
E. coli OP50.
Animals were age synchronised by hypochlorite treatment. The following strains were used in this study: Wild 
type N2, tdo-2 (del B) = OW715 tdo-2 (zg216)III; tdo-2 (del) = OW716 tdo-2 (zg217)III; tdo-2 (ΔPLD) = OW717 
tdo-2 (zg218)III.
NW7). Positioned nearby the haem, also in green, is the loop of residues MSPLDF which includes the PLD 
residues missing in the tdo-2 (ΔPLD) mutant. Amino acids on the C-terminal side of this loop are indicated 
in red. (c) Enlarged image of the X-ray structure of X. campestris TDO which contains haem (green) and the 
substrate L-Trp (orange, PDB identifier 1NW8)19. The PSE motif (yellow) is equivalent to the PLD motif in C. 
elegans. Through Glu 112, the motif interacts with monomer D of the tetramer, whereas through Tyr 113 and 
Arg 117, it forms part of the TDO active site. (d) Left: Enlarged image of MSPLDF loop in wild type C. elegans 
TDO-2. Right: Enlarged image of MSPLDF loop in C. elegans tdo-2 (ΔPLD) mutant. (e) Left: Enlarged image 
of MTALDF loop in wild type human TDO. Right: Enlarged image of MTALDF loop in human tdo (ΔALD) 
mutant.
www.nature.com/scientificreports/
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CRISPR/Cas9-induced mutagenesis. The target sequence was chosen as described in ref. 22. A target 
sequence in exon 3 (GCTCGACACAATGAGTCCAT) was selected for cloning. The target sequence was tested 
to be unique in the C. elegans genome (blast search on wormbase.org) to reduce the risk of off-target mutations. 
The target sequence was cloned into the pPD162 vector (C. elegans CRISPR/Cas9 vector from ref. 22) using 
the Q5 site-directed mutagenesis kit (New England Biolabs, E0554S). We used a forward primer including the 
target sequence (5′ -ctcgacacaatgagtccatGTTTTAGAGCTAGAAATAGCAAGT-3′ ) and a general reverse primer 
(5′ -CAAGACATCTCGCAATAGG-3′ ). Successful cloning was confirmed by sequencing at the site of integration 
as well as sequencing different sites of the vector.
Young adult wild type animals were injected with the CRISPR/Cas9 injection mix (50 ng/μ l of pPD162 including the 
target sequence and 10 ng/μ l of the CFP injection marker pPD136.61 (Fire Lab Vector Kit, 1999, linearised with ScaI) 
diluted in injection buffer23). The fluorescent injection marker was only used to control for successful injection. Single 
fluorescent progeny were isolated and checked for heterozygous mutations by sequencing and by the SURVEYOR® 
mutation detection kit from Transgenomics. Single progeny of heterozygous mutants were further isolated on individ-
ual plates and analysed for homozygous mutations (SURVEYOR® mutation detection and sequencing).
Metabolite measurements. Age-synchronised animals were transferred to NGM medium containing 
5-fluoro-2′ deoxy-uridine (FUDR) on day 1 of adulthood (day after larval stage 4) to prevent offspring from 
growing. On day 4 of adulthood, about 2000 animals/experimental group were washed off the plates with PBS and 
extensively washed to remove as much bacteria from cuticle and gut as possible. cOmpleteTM protease inhibitor 
(Roche) was then added and the samples were snap frozen. Only samples from the same experiment round were 
compared. The samples were lysed by sonication, excessive worm debris was removed and the protein concen-
tration was determined. The protein concentration of the different samples was equalised and tryptophan and 
kynurenine levels were measured by LC-MS/MS as described before8.
Immunodetection of TDO-2 in C. elegans. Lysates were generated as described under metabolite meas-
urements. Proteins were denatured for 10 minutes at 70 °C. Proteins were separated by SDS-PAGE (25 μ g total 
lysate per lane) and blotted to a PVDF membrane. The blot was blocked with 5% milk powder in PBS-Tween 
(0.1%). For immunodetection of TDO-2, we generated a C. elegans-specific polyclonal antibody in rabbits 
(Eurogentec, NL13061) against the peptide SEHSNLSHSQSSESD. The antibody was diluted 1:10,000 in 5% milk/
PBST and binding took place at room temperature for 1 hour. To visualise the binding of the anti-TDO-2 anti-
body, a HRP-coupled anti-rabbit antibody (mouse) was used.
Reproductive lifespan assay. Ten animals per condition were tested for their reproduction behaviour 
by transferring them every day to a fresh NGM plate. Eggs that were left behind could hatch and the number of 
hatched progeny was counted for the specific time period. Experiments were repeated and one representative 
graph is shown. Statistical analysis was by one-way ANOVA with post-hoc Bonferroni algorithm.
Motility. Age-synchronised animals were grown on FUDR-containing NGM medium from day 1 of adult-
hood onwards to prevent the growth of the offspring. Swimming assays were performed on 15 animals per exper-
imental group on different days of adulthood as indicated. For the assay, a single worm was placed in a drop of 
M9 buffer and was allowed to acclimate for 30 seconds before its swimming movements were counted for another 
30 seconds. Experiments were repeated 3 times and one representative graph is shown. Statistical analysis was by 
two-way ANOVA with post-hoc Bonferroni algorithm.
Lifespan experiments. 100 animals per experimental group were scored for their lifespan behaviour. 
Worms were age-synchronised and transferred to FUDR-containing NGM medium on day 1 of adulthood to 
prevent offspring from growing. The different mutations of the experimental groups were blinded before starting 
the experiment. At each time point, living animals were counted and dead animals (no longer showing nose touch 
response) removed. Animals that disappeared during the assay were excluded from the analysis. Experiments 
were performed at 20 °C and were repeated five times. One representative curve is shown. Curves were generated 
using Graphpad Prism software. Statistical analysis was by Log-rank (Mantel-Cox) algorithm.
Sequence alignment. The protein sequences for TDOs were retrieved from www.uniprot.org (H. sapiens: 
P48775, C. elegans: Q09474D. rerio: Q7SY53, D. melanogaster: P20351, X. leavis: Q5U4U6, M. musculus: P48776, 
R. norvegicus: P21643, accessed 18 Oct. 2016). Protein sequences were aligned using ClustalW2 or Clustal 
Omega. The default settings were applied (ClustalW accessed 18 July 2014, Clustal Omega 18 Oct. 2016)24. Haem 
and tryptophan binding sites were adopted from ref. 19.
Homology models for wild type and mutant C. elegans TDO-2. BLAST was used to search for the 
TDO molecule that in terms of X-ray structure had the most homology to C. elegans TDO-225. This turned out 
to be human TDO (ref. 20; PDB identifier 4PW8) with a sequence identity of 48.4%. On basis of this structure, 
models of the wild type and mutant proteins were built automatically using the SwissModel server26 and checked 
manually. In addition, we used the same crystal structure (4PW8) to model the structure of a human TDO where 
amino acids ALD were deleted at the equivalent position of PLD in the C. elegans enzyme. However, the human 
TDO X-ray structure (PDB identifier 4PW8) does not contain a haem moiety, which is critical for the catalytic 
activity of the enzyme. We therefore used the Coot program to superimpose the models of all TDO structures on 
the basis of secondary structures27. This demonstrated that the haem moiety of X. campestris TDO19 is perfectly 
positioned over the catalytic site of C. elegans TDO-2. This haem moiety was therefore added to our 3D models of 
wild type and mutant C. elegans TDO-2. All pictures were generated using Pymol software28.
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